Pioneering Research and Development in the Treatment of Addictions

R&D PUBLICATIONS
Our mission is to discover and develop innovative medications that help transform patients’ lives through our industry-leading understanding of addiction and its co-morbidities.

We are constantly investigating new areas of understanding, new approaches to addiction treatment and new methodologies to support measurement of clinical response. Our latest thinking, journals and studies in these areas include:

### Treatment of Substance Use Disorder

1. **Indivior: pioneering research and development in the treatment of addictions**
   - **Title of Article**: Indivior: pioneering research and development in the treatment of addictions
   - **Author**: Christian Heidbreder, Rolley E. Johnson, Chris Chapleo and Paul J. Fudala
   - **Publisher**: Nature, 522 (7557): Supp. S45-S63

### Treatment of Opioid Use Disorder

2. **A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of rbp-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence**
   - **Title of Article**: A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of rbp-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence
   - **Publisher**: J. Clin. Pharmacokinetics, 54(8): 837-849

3. **Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (child-pugh classes a, b, and c), in hepatitis c virus-seropositive subjects, and in healthy volunteers**
   - **Title of Article**: Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (child-pugh classes a, b, and c), in hepatitis c virus-seropositive subjects, and in healthy volunteers
   - **Publisher**: J. Clin. Pharmacokinetics, 54(8): 837-849

4. **Population pharmacokinetic modelling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder**
   - **Title of Article**: Population pharmacokinetic modelling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder
   - **Publisher**: J. Clin. Pharmacol., Oct 19th, Electronic publication ahead of print
Treatment of Psychiatric Co-Morbidities

5

Title of Article
Population pharmacokinetics and prediction of dopamine d2 receptor occupancy after multiple doses of rbp–7000, a new sustained–release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment

Author

Publishers

http://bit.ly/1iCNJ1v

Rescue Medications

6

Title of Article
Liquid chromatography/tandem mass spectrometry method for simultaneous determination of cocaine and its metabolite(-)ecgonine methyl ester in human acidified stabilized plasma samples

Author

Publishers
J. Chromatogr. B, 961: 77-85

http://bit.ly/1Rv24sU

Title of Article
A randomized, double-blind, placebo-controlled trial of RBP-8000 in cocaine abusers: Pharmacokinetic profile of RBP-8000 and cocaine and effects of RBP-8000 on cocaine-induced Physiological effects

Author

Publishers
J Addict Dis., 33(4): 289-302

http://bit.ly/1NPIGpN

Early Stage Discovery & Development

7

Title of Article
Rationale in support of the use of selective dopamine D3 receptor antagonists for the pharmacotherapeutic management of drug addiction

Author
Heidbreder C (2013)

Publishers
Naunyn-Schmiedeberg’s Archives of Pharmacology, 386: 167-176
